Teresa Macarulla Archives

NAPOLI-3: NALIRIFOX shows promise as first-line therapy in patients with metastatic pancreatic ductal adenocarcinoma

Metastatic Pancreatic Ductal Andenocarcinoma (mPDAC) is an aggressive type of cancer that is most frequently detected at advanced stages with…

VHIO establishes a large collection of cholangiocarcinoma models for preclinical drug evaluation and biomarker discovery

Recently published in Clinical Cancer Research*, a journal of the American Association for Cancer Research (AACR), VHIO investigators have established…

ESMO’s updated Clinical Practice Guideline: leading experts set out consensus recommendations for the diagnosis, treatment, and follow-up of oesophageal cancer

Published in the flagship journal of the European Society for Medical Oncology, Annals of Oncology, renowned leaders in the field…

Ivosidenib as a promising new contender against advanced cholangiocarcinoma

Cholangiocarcinoma (CCA) is a highly aggressive, heterogeneous disease that currently accounts for 15% of all liver cancers and approximately 3%…

VHIO is participating prominently in a study that seeks to evaluate the efficacy of a novel combination therapy in advanced pancreatic cancer

Ability Pharmaceuticals Announces the Inclusion of the First Patients in a Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as…

Newly appointed ESMO faculty: VHIO investigators join forces with other leading experts in oncology to deliver on ESMO’s Vision 2025

In parallel with the European Society for Medical Oncology’s (ESMO) publication of its 2025 Vision, which builds on the core…

Driving nano-based approaches closer to the clinic: Vall d’Hebron leads pilot study to assess the efficacy of nanoparticles against pancreatic cancer

The Horizon 2020 funded NoCANTher European Consortium*, coordinated by IMDEA Nanociencia, rolls out the clinical phase of the project. The…